Biotech Movers du jour: Clinical Data (CLDA) and Genoptix (GXDX)
Novartis (NVS) acquires Genoptix(GXDX $24.84) for $470M-Stock is up 25% The biotech diagnostics and tools sector was ignited today with acquisition of Genoptix, a provider of laboratory services for hematology and oncology. Genoptix put itself up for sale in December and is an emerging niche...
Venture Capital Recovers, Biotechnology Gets $3.7B in 2010
Venture Capitalists invested $21.8B in 2010 an increase of 19% over the prior year. Biotechnology was up 3% over the prior year to $3.7B with 460 deals. Software was the leader rising 20% to $4B. Medical Device was flat year over year with $2.3B invested. ANNUAL VENTURE INVESTMENT INCREASES FOR...
Rayno Life Science Portfolio 2011:Time to Raise a Little Cash
Time for Caution-Raise Cash After the Big Q4 2010 Run Here are some guidelines for the Rayno Life Science Portfolio: Smaller cap high beta biopharma stocks are at risk. No new buys. Our mid-cap index is still weak. Tools and diagnostics will be less volatile. ABAX, GPRO, ILMN. Raise cash or...
Biotech Stocks Sell-Off On Profit Taking: Traders Rule
Small to Mid Caps Off 3%+ Our Mid-Cap Index of biotech stocks was off 3% and more today. Among the big movers down on significant volume were: Alkermes (ALKS) down 4.19%, Arena (ARNA) down 4.25%, Biodel (BIOD) down 9.5%, Sangamo (SGMO) down 8.75%, Jazz (JAZZ) down 4.25% and Vivus (VVUS) down...
Reporting from the JPMorgan 29th Annual Healthcare Conference 2011
J.P.Morgan 29th Annual Healthcare Conference San Francisco, CA January 9-13 2011 Biotechnology: Bright Prospects For 2011 Rod Raynovich The J.P.Morgan Healthcare Conference was a hot ticket in a cold city with over 8500 attendees at the St.Francis Westin Hotel. Topcoats were the unlikely...